Fibrinopéptido A y cardiopatía isquémica aguda: valor diagnóstico y pronóstico: comunicación preliminar / Fibrinepectide A and acute ischaemic heart: diagnostic and prognostic value: preliminary communication

Debido a que la cardiopatía isquémica continúa siendo una de las primeras causas de mortalidad en nuestro país y a nivel mundial, es lógico entender el auge que han tenido los trabajos que involucren marcadores paraclínicos del fenómeno de la coagulación, debido al papel fundamental de ésta, en la fisopatología de dicha enfermedad, de allí nuestro interés en la investigación del rol que desempeña el fibrinopéptido A en el diagnóstico y pronóstico de la cardiopatía isquémica aguda. Por lo cual se realizó un estudio prospectivo, en donde se estudiaron 17 pacientes con cardiopatía isquémica aguda (13 angor y 4 IM), que ingresaron a la UCC del Hospital "Domingo Luciani", durante el lapso agosto-septiembre del año 94, a todos ellos se les tomó muestra al ingreso, a las 6 y a las 12 horas de su llegada al hospital, para derteminar los niveles plasmáticos de Fibrinopéptido A (marcador de la actividad de la trombina), así como también estudios paraclínicos convencionales (ECG, Enzimas Cardíacas, Rx de Tórax, ematología completa, Urea Creatinina, PTT, PT, Plaquetas). Analizando las relaciones existentes entre las diferentes variables mediante la técnica de Anova y T. Test; se evidencia que existe diferencia estadísticamente significativa entre el grupo control y los pacientes con cardiopatía isquémica aguda (IM y Angor) en los niveles de fibrinopéptido A, dando valores de P=0.036 demostrando de esta manera, la utilidad de este marcador en la cardiopatía isquémica aguda

Fibrinopeptide A: an indicator of increased thrombin activity in diabetes mellitus

To determine the role of Fibrinopeptide [FPA] in vascular complication in diabetics, it is estimated by a sensitive RIA technique in7 control subjects and 28 diabetics classified according to their line of treatment into IDD and NIDD who were further subdivided into those with vascular complications and those without vascular complications. Results showed that diabetics as a whole had a significantly higher mean values of both fasting and postprandial FPA compared to controls. A significant difference for fasting FPA was noticed between non complicated IDD and NIDD [P < .05], between complicated IDD and non complicated NIDD [P < 0.01] and between non complicated NIDD and complicated NIDD [P < 0.01]. Postprandial FPA was significantly higher in non complicated IDD, non complicated NIDD and complicated NIDD compared to controls [P > 0.05, P > 0.01 and P < 0.05 respectively]. Uncomplicated diabetics had a significantly higher mean fasting FPA level [P < 0.05] compared to complicated but not regarding to postprandial FPA. Finally a significant positive correlation was observed between fasting FPA versus fasting blood glucose in non complicated NIDD [r = 0.85, P < 0.05] and complicated NIDD [r = 0.86, P < 0.05], also between postprandial FPA and both fasting FPA [r = 0.94, P < 0.01] and fasting blood glucose [r = 0.91, P < 0.01] in complicated NIDD. It may be concluded that elevated FPA level in diabetes is considered as a sensitive specific parameter of in vivo thrombin activation in diabetes [Hypercoagulable state]. This elevation is associated with diabetes more than being associated with vascular complication

Study of fibrinopeptide A, fibrin monomer and fibrin degradation products in non-insulin dependent diabetes mellitus

The study was carried out on 20 non-insulin dependent diabetics and 10 healthy adult control subjects. The work aimed at estimation of fibrinopeptide A [FPA], fibrin monomer [FM] and fibrin degradation products [FDP] in non-insulin dependent diabetic patients with and without vascular complications, in addition to euglobulin clot lysis time [EGCLT], blood sugar, serum triglycerides, serum cholesterol, HDL-cholesterol and LDL-cholesterol. Serum fibrinopeptide-A [FPA] level was elevated in diabetics with vascular complications, reflecting augmented thrombin activity. EGCLT showed significant prolongation in diabetics with vascular complications. Pathological levels of FDP were detected in three diabetic patients [30%] with vascular complications. The significance of these findings were then analyzed and discussed